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A variety of enzyme inhibitors have been developed in combating HIV-1, however the fast evolutionary rate of this virus commonly
leads to the emergence of resistance mutations that finally allows the mutant virus to survive. This review explores the main
genetic consequences of HIV-1 molecular evolution during antiviral therapies, including the viral genetic diversity and molecular
adaptation.The role of recombination in the generation of drug resistance is also analyzed. Besides the investigation and discussion
of published works, an evolutionary analysis of protease-coding genes collected from patients before and after treatment with
different protease inhibitors was included to validate previous studies. Finally, the review discusses the importance of considering
genetic consequences of antiviral therapies in models of HIV-1 evolution that could improve current genotypic resistance testing
and treatments design.
1. Introduction
According to UNAIDS, the Joint United Nations Programme
on HIV/AIDS World Health Organization, a total of 35.3
[32.2–38.8]million people worldwide were living with HIV-1
in 2012, indicating a ∼15% increase of infected people from
2001 [1]. A total of 2.3 [1.9–2.7] million were newly infected
during 2012, showing a 33% decline of new infections from
2001 with 3.4 [3.1–3.7] million. Indeed, the number of AIDS
deaths declined from 2.3 [2.1–2.6] million in 2005 to 1.6
[1.4–1.9] million in 2012 [1]. An important cause for such a
death decline is the antiretroviral therapy, usually referred to
as highly active antiretroviral therapy (HAART). In 2012, a
total of 9.7million people from low/middle-income countries
receivedHAARTand theUNAIDS expects to reach 15million
people receiving HAART by 2015 [1]. Nevertheless, in 2013
only 34% of people infected with HIV in low/middle-income
countries (28.6 million) could receive therapy [1]. Therefore,
there are still important regional differences that should be
solved [2, 3]. On the other hand, the development of an
effective HIV vaccine is still under progress with a number
of failures [4] because of the high rate of evolution of HIV-
1 [5, 6]. As a consequence, up to date the only treatment for
HIV-1 is the antiretroviral drug therapy.
HAART have largely delayed the onset of AIDS-related
illness and death [1] although they cannot eradicate the virus
mainly due to latent viral reservoirs [7]. In addition, drug
resistance mutations can reduce the activity of the therapy
[8, 9]. Drug resistance mutations probably emerge because
HIV evolves rapidly, with high mutation and recombination
rates and under rapid population dynamics [10]. Of course,
then natural and drug-induced selection can eliminate
most of viral variants [11]. The surviving variants (8–20%)
present drug resistance mutations, which allows recovering
fitness and replication capacity [8, 12]. Interestingly, different
inhibitors can generate different selective pressures that
induce the fixation of different resistance mutations in the
viral population but also different resistance mutations may
affect different inhibitors in a different fashion. This suggests
the simultaneous use of more than one inhibitor that could
cover a wider range of mutations [13], although this strategy
may fall into similar resistance (cross-resistance) and lack of
synergy [14, 15].
A potential strategy to deal with the problem of resis-
tance mutations could be the consideration of the molecular
evolution of the virus [16, 17] into the inhibitor design. For
example, inhibitors that account for molecular evolutionary
processes of the virus could eliminate viral variants that could
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be predicted beforehand. Actually, this promising strategy is
commonly applied to HIV-1 vaccines design through the use
of centralized (consensus, center-of-tree or ancestral) genes
that can induce immune responses (reviewed in [17]). Such
centralized sequences could consider the immunogenetic
particularities of the diverse circulating variants in the target
population [18, 19]. However, although these centralized
vaccines generated promising antibody responses, they were
only partially effective in covering the large HIV-1 genetic
diversity. Perhaps this could be derived from the appli-
cation of not enough realistic models of HIV-1 evolution
as suggested in [17]; see also [20]. Knowledge on HIV-1
molecular evolution can also be used to develop realistic
models of evolution [21, 22] that can be applied for additional
purposes such as the prediction of resistance mutations [23]
or the evolutionary reply of the viral population, genotypic
resistance testing [24, 25].
This study explores the genetic consequences of antiviral
therapy on HIV-1. First, it analyzes the influences of antiviral
therapies on the viral genetic diversity, including the partic-
ular roles of the substitution and recombination processes in
the generation of drug resistance. Then, the molecular signa-
tures of selective pressures derived from antiviral therapies
are evaluated. A brief evolutionary analysis of the influence
of different protease (PR) inhibitors (PIs) on the PR-coding
region was performed to evaluate previous works and to
provide an illustrative example.The application of the genetic
consequences derived from antiviral therapies in the devel-
opment of new empirical substitution models that could be
used for purposes such as genotypic resistance testing and
treatments design is also discussed.
2. Genetic Diversity Generated during
HIV-1 Antiviral Therapy
Interestingly, the effects of HIV-1 antiviral drugs on the viral
genetic diversity depend on the evolutionary level under
study. It differs from overall diversity of circulating strains in
the viral population to local nucleotide diversity of particular
viral genes.
The antiviral therapy can reduce the global viral genetic
diversity in the population due to the selection of viral strains
[26–28]. This phenomenon can be interpreted as a classi-
cal population range contraction and habitat fragmentation
that commonly tend to decrease genetic diversity [29, 30].
Actually, a variety of population genetics analysis of HIV-1
showed the existence of severe population bottlenecks (loss
of viral load) and loss of virus fitness during drug regimens
[28, 31, 32].
In contrast, the survival strains may present drug resis-
tance mutations [33] that often increase genetic diversity of
the protein-coding genes of the target proteins [12, 34, 35].
Wu et al. [36] found that patients treated with several PIs
presented 3 times more protease mutations than untreated
patients. These findings are also observed in the computa-
tional analysis presented in the last section of this paper
wheremost of PIs promoted higher levels of nucleotide diver-
sity in the PR-coding gene. Interestingly, pairs and clusters
of correlated resistance mutations (coevolution) were signifi-
cantly more abundant in treated patients [36]. Consequently,
the increased diversity does not follow a random process,
instead the new mutations present residue-residue interac-
tions from direct association with viral protein inhibitors
[23]. Increased genetic diversity can also be observed under
treatment with other antiviral drugs such as reverse tran-
scriptase (RT) inhibitors [34, 37–39] and integrase (IN)
inhibitors [40–43], although the increased diversity under
the latter drug class is mainly based on secondary resistance
mutations [40–43]. Indeed, combinations of different drug
classes (acting on different HIV-1 proteins) can generate
synergistic inhibition [44] but the overall presence of synergy
on genetic diversity remains to be explored, although some
mutations in theEnv region have already been associatedwith
resistance to entry inhibitors that affect other viral genes [9].
Overall, at this level, the molecular mechanisms by which
the virus can evade treatments seem directly related with
the virus’s ability to generate genetic diversity in a particular
environment. Thus, this increased genetic diversity could be
driven by strong selective pressures (discussed later).
3. The Role of Viral Recombination during
HIV-1 Antiviral Therapy
Recombination constitutes a fundamental evolutionary force
inHIV generating new viral strains, increasing viral diversity,
and facilitating adaptation [45–47]. Indeed, ignored recom-
bination can bias the inference of a variety of evolutionary
processes and parameters (i.e., it can increase the number of
false positively selected sites [48, 49] or generate incorrect
phylogenetic tree and ancestral sequence reconstructions [50,
51]). Therefore recombination should be taken into account
for analyzing and understanding HIV-1 evolution.
The role of recombination on the emergence of drug resis-
tancemutations is not yet clear and it can be difficult to assess
because other processes may also influence its evolutionary
consequences (i.e., cellular superinfection [52–54], random
genetic drift, and viral population size [55, 56] or fitness
selection of the newly generated viral forms [57, 58]) and
because the detection of recombination can be problematic
under low levels of nucleotide diversity [59]. Contradictory
effects of recombination during HIV-1 antiviral therapy can
be found in the literature.
As one would expect beforehand, several studies showed
that recombination is crucial to generate drug resistance.
A computer simulations study suggested that recombina-
tion might favor the generation of drug resistance [60]. In
addition, HIV-1 strains derived from recombination events
presented resistance mutations [61, 62].
On the contrary, Archer et al. [63] showed that despite
the wide diversity of recombinant forms in HIV populations,
only aminority of recombination events are of significance to
the evolution of the virus. Counterintuitively, it has also been
demonstrated that recombination can slow down the gener-
ation of multi-drug-resistant strains during therapy [52] and
it may be suppressed by selection for resistance to PIs [64].
It seems that the initial genetic barrier caused by recom-
bination (most of recombinant forms could present low
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fitness) could reduce the fitness of the viral population during
the therapy but in case a recombinant form is selected,
resistancemutations could be better able to persist in the viral
population [54] and speed up adaptation (the Fisher-Muller
effect) [65]. In any case, these opposite findings suggest
that more sophisticated analyses should be performed to
determine the influence of recombination on the emergence
of drug resistance mutations, as suggested by Shi et al. [61].
4. Selective Pressures Induced by
HIV-1 Antiviral Therapy
Antiviral therapy may cause important selective pressures on
viral populations [12, 66]. In particular, severe fitness losses
can be derived from antiviral treatments until the emergence
of beneficial mutations that allow restoring the vital replica-
tion capacity [12].Thus, resistance to viral inhibitors can drive
the fixation of favorable variants [23, 67].
The overall response to antiviral drugs presented an
excess of nonsynonymous substitutions [23, 68] (which was
also found in the analysis presented in the following section).
For example, Wu et al. [36] found that an antiviral therapy
can induce diversifying selection in nearly one-half of PR
sites. It is widely known that positively selected sites (PSSs)
are often located in the protein surface, whereas conserved
or negatively selected sites (NSSs) are commonly observed
in the protein core in order to conserve the protein function
[69]. However, the molecular adaptation induced by antiviral
therapies does not present such a scenario. Poon et al. [23]
found that the distribution of nonsynonymous substitutions
along the gene is shaped by selection to PI resistance.
Moreover, antiviral therapies promote complex drug-specific
residue-residue interaction networks [23, 70, 71] that can
drive the coevolution of primary and secondary resistance
mutations [8, 23].
5. Genetic Impact of Diverse PIs on HIV-1
PR-Coding Genes: A Computational Study
The HIV-1 PR is one of the most used drug targets for com-
bating HIV with a number of chemically diverse inhibitors
that have already been tested [72, 73]. This section includes a
computational analysis of nucleotide diversity and molecular
adaptation of the PR-coding gene evolution under different
PIs.
5.1. Sample Collection. Samples of coding DNA sequences
that encode the HIV-1 PR (Pol region, subtype B) were
collected from the Stanford HIV Drug Resistance Database
[74, 75]. Subtype B was used because most (∼99%) of datasets
available in the database belong to this subtype and there is
not enough data to analyze other subtypes. For each HIV-1
patient, a clonal sequence was collected under no-treatment
and another one was collected after a particular treatment
based on a single PI or a PIs combination. According to
the detailed information provided by the database [74, 75],
the patients did not receive other treatments. Therefore, to
study each treatment (hereafter, evolutionary scenario) two
datasets (pool of sequences before and after treatment) were
obtained. In particular, for each evolutionary scenario, a
dataset includes coding sequences collected before a given
treatment and the other dataset includes coding sequences
collected after such a treatment, and both datasets come from
the same patients. As suggested by Kosakovsky Pond and
Frost [76], scenarios with sample size lower than 10 were
not considered to avoid lack of power in the evolutionary
analysis (datasets with higher sample size can generate
accurate estimates of genetic diversity and nonsynonymous
to synonymous substitution rates ratio (dN/dS) [76]; see also
[3, 77]). A total of 13 evolutionary scenarios, all the currently
available scenarios from the database, were analyzed. Namely,
a “control” scenario (no-treatment in both datasets, scenario
1, 1011 patients) and scenarios with the following treatments:
amprenavir (APV, scenario 2, 15 patients), atazanavir (ATV,
scenario 3, 23 patients), indinavir (IDV, scenario 4, 77
patients), lopinavir (LPV, scenario 5, 34 patients), nelfinavir
(NFV, scenario 6, 317 patients), ritonavir (RTV, scenario 7,
24 patients), saquinavir (SQV, scenario 8, 35 patients), and
the PI combinations: IDV + RTV (scenario 9, 10 patients),
RTV + SQV (scenario 10, 11 patients), and IDV + RTV + SQV
(scenario 11, 11 patients). Two additional scenarios were also
studied where patients treated with IDV are then treated with
IDV+NFV (scenario 12, 13 patients) or IDV+RTV (scenario
13, 16 patients).
5.2. Analysis of Genetic Diversity and Recombination. Several
genetic statistics were applied to study the influence of PIs on
the genetic diversity of the PR-coding gene. (i) The overall
sequences divergence was computed with MEGA 6.0 [78].
(ii) Nucleotide diversity (𝜋) was estimated by using the
pairwise nucleotide differences per site [79]. These metrics
considered indels as missing data. (iii) The genetic distance
between the two datasets of each evolutionary scenario was
computed by the Kullback-Leibler (KL) divergence [80] and
considering indels as missing data and as an additional state.
This distance provides a comparative analysis of nucleotide
diversity distributions across sites between two datasets [81].
Briefly, the results show that almost all PIs lead to higher
levels of sequences divergence, pairwise nucleotide diversity,
and nucleotide diversity distribution across sites. Except
for LPV and NFV, all PIs increased the overall difference
between sequences (Figure 1(a)). Similar results are derived
from the estimates of nucleotide diversity although here only
LPV presented low levels of nucleotide diversity variation
(see Figure S1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2015/395826). The highest levels of
diversity were generated from treatment with APV, IDV, and,
especially, PIs combinations. However, the increase of diver-
sity could be caused by the emergence of resistancemutations
but also by mutations derived from the natural evolution of
the gene.Therefore, it is interesting to evaluate the correlation
between the variation of diversity and the corresponding
time period between samples. Figure 2(a) suggests that
there is no correlation between these parameters, which is
supported by a low correlation coefficient (𝑟 = 0.056). For
example, the control dataset (no-treatment) does not present
increase of diversity despite its long time period (11 months),
whereas treatment with APV generated one of the highest
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Figure 1: Overall sequence diversity variation and Kullback-Leibler
divergence. (a) Variation of overall sequence difference between
the two datasets of each evolutionary scenario (𝑑after treatment −
𝑑before treatment). Indels are considered as missing data. Error bars
indicate standard error. Reference values are shown in Table S1 (Sup-
plementary Material). (b): Kullback-Leibler distance, nucleotide
diversity distribution, between the two datasets of each evolutionary
scenario. Dark grey bars consider indels as a new state whereas
clear grey bars consider indels as missing data. Error bars indicate
standard error across sites. “−” indicates naı¨ve-treatment patients.
levels of diversity in only 4 months (Figure 2). In addition,
correlation coefficients within scenarios (among patients
from a particular scenario) were also very low, most of them
under 0.1 (Figure 2(a)). A normalization dividing the genetic
diversity gradient by the time period between samples also
indicated the increase of genetic diversity with most of PIs
(Figure 2(b)). However, the normalization must be carefully
interpreted because a longer time period does not necessarily
lead to more diversity [82], which is actually indicated by the
described lack of correlation.
The analysis of nucleotide diversity distribution across
sites between the two alignments showed similar findings
for most of PIs (Figure 1(b)). Notice that this nucleotide
distribution can be more influenced by several mutations
at specific positions [80] and therefore this statistic might
be more sensible to detect resistance mutations. The results
show an influence of all PIs on the nucleotide diversity dis-
tribution (Figure 1(b)), although this influence varies among
inhibitors. Again, the long KL distance derived from drug
combination therapies is remarkable.
0.0
0.5
1.0
1.5
2.0
2.5
0 10 20 30 40 50 60
Time period (months)
−/RTV, SQV
−/IDV, RTV, SQV
−0.5
r = 0.016
r = 0.060
r = 0.507
r = 0.189
r = 0.034
r = 0.018
r = 0.0004
r = 0.003
r = 0.001
r = 0.069
r = 0.0003
r = 0.084
r = 0.258
r = 0.056
−/APV
−/RTV
−/ATV
−/SQV
−/LPV−/NFV
−/IDV
−/−
−/IDV, RTV
IDV/IDV, NFV
IDV/IDV, RTV
Se
qu
en
ce
 d
iff
er
en
ce
 v
ar
ia
tio
n 
(%
)
(a)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
Se
qu
en
ce
 d
iff
er
en
ce
 v
ar
ia
tio
n/
−0.1
tim
e p
er
io
d
Evolutionary scenario
RT
V
SQ
V
N
FV
RT
V
SQ
V
ID
V
/ID
V,
ID
V
/ID
V,
−
/−
−
/A
PV
−
/A
TV
−
/ID
V
−
/L
PV
−
/ID
V,
−
/R
TV
,
−
/ID
V,
 R
TV
,
−
/S
Q
V
−
/R
TV
−
/N
FV
(b)
Figure 2: Sequence difference variation as a function of time
interval between samples. (a) Variation of the overall sequence
difference between the two datasets of each evolutionary sce-
nario (𝑑after treatment − 𝑑before treatment) is represented in the “𝑦-axis”
(mean and standard error). The time period between both samples
(𝑡after treatment − 𝑡before treatment) is represented in the “𝑥-axis” (mean
and standard error from all patients of the scenario).The correlation
coefficient between both parameters among all the scenarios is 𝑟 =
0.056, suggesting absence of correlation. Correlation coefficients
within each evolutionary scenario (among patients) between these
parameters are also shown in the plot and ranges from 0.0003 to
0.507, although most of them are under 0.1. (b) Genetic diversity
gradient divided by the corresponding time period. Error bars
indicate standard error. “−” indicates naı¨ve-treatment patients.
Reference values are shown in Table S1 (Supplementary Material).
Absence of recombination breakpoints was found with
the single breakpoint position (SBP) method [83], imple-
mented in the Hyphy package [84], and with the recombina-
tion detection methods implemented in the RDP framework
[85].
5.3. Signatures of Molecular Adaptation. The best-fit model
of DNA substitution was selected with jModelTest [86] under
the Bayesian information criterion (BIC), as suggested by
[87]. Then, maximum likelihood (ML) phylogenetic trees
were inferred with PhyML [88] under the corresponding
substitution model. These trees were used to perform the
molecular adaptation inferences. Estimates of dN/dS at both
global (sequence) and local (codon) levels were performed
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Figure 3: Global nonsynonymous to synonymous substitution rates
ratio (dN/dS) variation. Variation of global dN/dS between the
two datasets of each evolutionary scenario (𝑑𝑁/𝑑𝑆after treatment −
𝑑𝑁/𝑑𝑆before treatment). Error bars indicate 95% CI. “−” indicates
na¨ıve-treatment patients. Reference values are shown in Table S3
(Supplementary Material).
with the Fixed Effects Likelihood (FEL) method [76] imple-
mented in the Hyphy package. Notice that this ML-based
method provides very accurate estimates [76] and it is
commonly used in population genetics and virus evolution
(e.g., [3]).
Figure 3 shows the variation of global dN/dS estimates
from datasets collected before and after a treatment. All the
PIs promoted increased estimates of dN/dS, especially when
the treatment is based on PIs combination. By contrast, in
absence of treatment the estimated dN/dS declined with time.
At the local level, almost all the PIs promoted an increase
of significant (𝑝 value < 0.05) PSSs along the PR-coding
sequence (Figure S2 and Table S4, Supplementary Material).
In general, a large number of NSSs were detected in all
datasets (Table S4) without showing a clear relationship with
the presence or absence of treatment. All these results are
discussed in the next section.
6. Concluding Remarks
The fast population range contractions and fragmentation
produced during the therapy can reduce the overall diversity
of viral strains [29] and, by contrast, the emergence of
resistance mutations caused from the rapid evolution of HIV
allows preserving or increasing the levels of nucleotide diver-
sity of viral protein-coding genes of the drug target. Indeed,
resistance mutations can be rare, but also recurrent enough
until they reach resistance, and can generate positive selection
driving the fixation of favorable viral strains [23, 67]. At this
level two opposite selective pressures seem to act.While most
of sites evolve under strong purifying selection, probably
caused by the host’s immune system and the therapy, other
sites evolve under diversifying selection, probably caused
by the viral molecular adaptation to the new environment
established by the therapy, and can present complex residue-
residue interaction networks suggesting dependent evolution
among sites [23, 70].
The evolutionary analysis included in this work sup-
ported such considerations. It also showed that different PIs
can promote different influences on the genetic diversity
of the viral PR-coding gene. For example, IDV and APV
induced the highest levels of diversity (among treatments
with a single PI) and PIs combination induced very high
levels of genetic diversity, especially when 3 PIs are applied
jointly. As noted, this increase of diversity can be related with
the emergence of resistance mutations [33]. The reason why
some inhibitors induce more diversity than others requires
complex structural analysis of enzyme-inhibitor interactions,
which is an important topic of research [89, 90]. On the other
hand, absence of recombination breakpoints was found in
the analyzed PR-coding genes. This could be caused by lim-
itations to detect recombination under low genetic diversity
levels [59] or just because recombination was not required to
generate drug resistance. Indeed, recombination could occur
in other genomic regions [63] (i.e., recombinants with break-
points in Gag and Polmay present selection against [63, 91]).
Concerningmolecular adaptation, the results showed that the
wild evolution of the virus presents an overall decrease of the
global dN/dS, without PSSs and where most of sites evolved
under significant purifying selection.This is probably caused
by the sharp purifying selection induced by the host’s immune
system. On the other hand, PIs often promoted an overall
increase of the global dN/dS (see [23, 68] and Figure 3), which
is most of times accompanied by the emergence of significant
PSSs along the gene (see [23] and Figure S2). As expected,
the largest dN/dS increase occurs under treatments with PIs
combination (see [23] and Figure 3). These signatures of
molecular adaptation are related with the amount of genetic
diversity induced by the PIs and indicate the primary impor-
tance of adaptation in the evolutionary process of the PR-
coding gene under PIs. On the other hand, a large number of
codons evolved under negative (purifying) selection, which
indicates the presence of strong selective pressures, as noted
probably caused by the host’s immune system and the therapy.
Understanding molecular evolution of the virus can help
us develop more realistic models of HIV evolution [23, 69,
71], correlate the disease progression with the evolution of
the viral population [28, 92], and predict resistance (i.e., by
genotypic-resistance testing [24, 25, 93, 94]) and common
ancestry [18], or vaccine design [17–19]. Nevertheless, HIV-
1 evolution is complex and other phenomena should also be
taken into account as much as possible in the models, for
example, different host’s immune responses, clinical stage,
HIV-1 compartmentalization [95], or infection with multiple
viral variants, although the latter presents an overall low
incidence [53, 96].
Since antiviral therapies affect genetic diversity of the
virus by strong selective pressures, models of HIV-1 evolution
should accommodate such effects in order to mimic these
scenarios for purposes such as robust genotypic resistance
testing and treatments design. Importantly, models of HIV-1
evolution should be as realistic as possible in order to provide
accurate predictions. A possibility could be the consideration
of a fitness landscape (e.g., [97]) to develop parametric
models. However, the design and computation of a realistic
fitness function are too convoluted due to complex processes
6 Computational and Mathematical Methods in Medicine
that affect viral genetic diversity such as antiviral therapies (as
noted in this paper). An easier, but less robust, alternative can
be the development of scenario-specific empirical models.
As shown in this paper, different therapies must be modeled
with different models of evolution since different therapies
can promote different genetic consequences in the virus.
Much more research is needed (i.e., the consideration of
associations between observed genotypes and phenotypic
resistance in models of HIV-1 evolution) but my impression
is that HIV-1 therapies will benefit from more consideration
of evolutionary information.
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